Home›Clinical trials›Pennsylvania

GLP-1 clinical trials in Pennsylvania: 32 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

32 GLP-1 clinical trials are recruiting at 50 sites in 19 cities across Pennsylvania. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Pennsylvania

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in Pennsylvania

    NCT05390892 on ClinicalTrials.gov. See whether you qualify.

  2. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    1 site in Pennsylvania

    • Dermatology Associates of Plymouth Meeting, Plymouth Meeting

    NCT06857942 on ClinicalTrials.gov. See whether you qualify.

  3. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    5 sites in Pennsylvania

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  1. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    4 sites in Pennsylvania

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

  2. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Boehringer Ingelheim plans to enroll 600 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    4 sites in Pennsylvania

    • Heritage Valley Medical Group, Beaver. 833-602-2368
    • Preferred Primary Care Physicians, Pittsburgh. 833-602-2368
    • Preferred Primary Care Physicians-Pittsburgh-63932, Pittsburgh. 833-602-2368
    • Preferred Primary Care Physicians - Matthew Drive, Uniontown. 833-602-2368

    NCT07754461 on ClinicalTrials.gov. See whether you qualify.

  3. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    3 sites in Pennsylvania

    • US Digestive Health - Flourtown, Flourtown. 215-664-4362
    • Penn Medicine: University of Pennsylvania Health System, Philadelphia
    • US Digestive Health - Wyomissing, Wyomissing. 610-374-4401

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  4. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    3 sites in Pennsylvania

    • Heritage Valley Medical Group, Beaver
    • Hatboro Med Associates, Hatboro
    • Northeast Endocrine Metabolic Associates, Philadelphia

    NCT07564414 on ClinicalTrials.gov. See whether you qualify.

  5. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Eli Lilly and Company plans to enroll 1,000 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    2 sites in Pennsylvania

    • OB/GYN Associates of Erie, Erie
    • Clinical Research of Philadelphia, Philadelphia. 215-676-6696

    NCT07202884 on ClinicalTrials.gov. See whether you qualify.

  6. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. VA Office of Research and Development plans to enroll 622 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    2 sites in Pennsylvania

    • Corporal Michael J. Crescenz VA Medical Center, Philadelphia. 2158235800
    • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia. (215) 823-5894

    NCT07218354 on ClinicalTrials.gov. See whether you qualify.

  7. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    2 sites in Pennsylvania

    • Research Site, Feasterville-Trevose
    • Research Site, Philadelphia

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

The other 22 studies recruiting in Pennsylvania

  1. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Pennsylvania

    • UPMC Children's Hospital of Pittsburgh, Pittsburgh. 412-692-6935

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  2. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Eli Lilly and Company plans to enroll 150 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in Pennsylvania

    • Childrens Hospital of Pittsburgh, Pittsburgh

    NCT06672939 on ClinicalTrials.gov. See whether you qualify.

  3. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Eli Lilly and Company plans to enroll 350 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Pennsylvania

    • Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia. 215-955-8900

    NCT06937086 on ClinicalTrials.gov. See whether you qualify.

  4. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Eli Lilly and Company plans to enroll 290 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in Pennsylvania

    • Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia. 215-955-8900

    NCT06937099 on ClinicalTrials.gov. See whether you qualify.

  5. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in Pennsylvania

    • University Orthopedics Center, Altoona

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  6. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Eli Lilly and Company plans to enroll 1,205 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    1 site in Pennsylvania

    NCT07223593 on ClinicalTrials.gov. See whether you qualify.

  7. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 460 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    1 site in Pennsylvania

    • UPMC Child Hosp-Pittsburgh, Pittsburgh

    NCT07253285 on ClinicalTrials.gov. See whether you qualify.

  8. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Amgen plans to enroll 300 participants.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    1 site in Pennsylvania

    • Altoona Center for Clinical Research, Duncansville

    NCT07575399 on ClinicalTrials.gov. See whether you qualify.

  9. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 450 participants.

    A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    1 site in Pennsylvania

    • UPA Ctr Weight and Eating Dis, Philadelphia

    NCT07770841 on ClinicalTrials.gov. See whether you qualify.

  10. Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

    Phase 2. Dan Zandberg plans to enroll 72 participants.

    A study of nivolumab or pembrolizumab in people with melanoma.

    Who can join. Adults 18+, have melanoma.

    1 site in Pennsylvania

    NCT04114136 on ClinicalTrials.gov. See whether you qualify.

  11. GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

    Phase 2. University of Pennsylvania plans to enroll 30 participants.

    A study testing whether a GLP-1 medicine, dulaglutide, can help people with cystic fibrosis lower blood sugar.

    Who can join. Adults 18+, have cystic fibrosis, BMI 19+.

    1 site in Pennsylvania

    NCT04731272 on ClinicalTrials.gov. See whether you qualify.

  12. GLP-1R Agonist Treatment for Opioid Use Disorder

    Phase 2. Milton S. Hershey Medical Center plans to enroll 200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18 to 75, have opioid use disorder, BMI 18+.

    1 site in Pennsylvania

    NCT06548490 on ClinicalTrials.gov. See whether you qualify.

  13. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Eli Lilly and Company plans to enroll 240 participants.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    1 site in Pennsylvania

    NCT06897475 on ClinicalTrials.gov. See whether you qualify.

  14. Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

    Phase 2. Alaa Sada plans to enroll 34 participants.

    A study of a GLP-1 and GIP medicine, tirzepatide, in people with mild autonomous cortisol secretion (MACS).

    Who can join. Adults 18+, have mild autonomous cortisol secretion (MACS), BMI 27+.

    1 site in Pennsylvania

    • University of Pittsburgh Medical Center, Pittsburgh

    NCT07573163 on ClinicalTrials.gov. See whether you qualify.

  15. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Novo Nordisk A/S plans to enroll 230 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in Pennsylvania

    • UPA Ctr Weight and Eating Dis, Philadelphia

    NCT07639021 on ClinicalTrials.gov. See whether you qualify.

  16. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 300 participants.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Pennsylvania

    • Preferred Primary Care Physicians, Inc., Uniontown

    NCT07668388 on ClinicalTrials.gov. See whether you qualify.

  17. Pharmacogenetics of Response to GLP1R Agonists

    Phase 1. University of Maryland, Baltimore plans to enroll 600 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18 to 89, have obesity, BMI 27+.

    1 site in Pennsylvania

    NCT05071898 on ClinicalTrials.gov. See whether you qualify.

  18. Feasibility of Semaglutide in Advanced Lung Disease

    Phase 1. University of Pennsylvania plans to enroll 8 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with interstitial lung disease lose weight.

    Who can join. Adults 18 to 80, have obesity, BMI 30+.

    1 site in Pennsylvania

    • University of Pennsylvania Perelman School of Medicine, Philadelphia

    NCT05746039 on ClinicalTrials.gov. See whether you qualify.

  19. Beta-cell Response to Incretin Hormones in Cystic Fibrosis

    University of Pennsylvania plans to enroll 45 participants.

    A study in people with cystic fibrosis.

    Who can join. Adults 18+, have cystic fibrosis.

    1 site in Pennsylvania

    • Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia. 215-746-2081

    NCT01851694 on ClinicalTrials.gov. See whether you qualify.

  20. Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication

    Penn State University plans to enroll 25 participants.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18+, BMI 25+.

    1 site in Pennsylvania

    • Health, Ingestive Behavior, and Technology Laboratory of Pennsylvania State University, State College. 425-499-8049

    NCT06843512 on ClinicalTrials.gov. See whether you qualify.

  21. Transformative Research in Diabetic Nephropathy 2.0

    University of Pennsylvania plans to enroll 200 participants.

    A study testing whether a study medicine, Sodium-glucose cotransporter 2 inhibitors (SGLT2i), can help people with diabetic kidney disease protect their kidneys.

    Who can join. Adults 18+, have diabetic kidney disease.

    1 site in Pennsylvania

    • Penn Presbyterian Medical Center, Philadelphia. 2673030158

    NCT07444203 on ClinicalTrials.gov. See whether you qualify.

  22. The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication

    University of Pittsburgh plans to enroll 40 participants.

    A study in adults starting a GLP-1 medicine on their own prescription.

    Who can join. Adults 18+, have obesity, BMI 27+.

    1 site in Pennsylvania

    • Physical Activity Research Center, University of Pittsburgh, Pittsburgh. 515-817-4601

    NCT07652333 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.